Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.55M | 4.53M | 1.83M | 1.83M | 1.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.55M | 4.53M | 1.83M | 1.83M | 1.61M |
| Cost of Revenue | 3.47M | 3.46M | 1.16M | 1.16M | 1.12M |
| Gross Profit | 1.08M | 1.07M | 670.50K | 671.00K | 486.50K |
| SG&A Expenses | 1.27M | 1.27M | 1.09M | 1.09M | 710.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -231.90K | -231.30K | -4.60K | -4.60K | -38.70K |
| Total Operating Expenses | 4.51M | 4.50M | 2.24M | 2.24M | 1.79M |
| Operating Income | 36.80K | 36.70K | -413.50K | -413.80K | -185.70K |
| Income Before Tax | 45.30K | 45.20K | -397.10K | -397.40K | -148.10K |
| Income Tax Expenses | 167.10K | 166.70K | 1.00K | 1.00K | -- |
| Earnings from Continuing Operations | -121.90K | -121.60K | -398.10K | -398.40K | -148.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -277.30K | -276.70K | 70.10K | 70.20K | -- |
| Net Income | -399.20K | -398.30K | -328.00K | -328.30K | -148.10K |
| EBIT | 36.80K | 36.70K | -413.50K | -413.80K | -185.70K |
| EBITDA | 146.90K | 146.50K | -376.60K | -376.90K | -179.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 679.25M | 679.25M | 650.68M | 650.68M | 639.30M |
| Average Diluted Shares Outstanding | 679.25M | 679.25M | 650.68M | 650.68M | 639.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |